Company Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-06-13 EDT			5-day change	1st Jan Change
6.920 ^USD	-3.22%		+23.13%	-4.02%

05-23	Altimmune, Inc., Q1 2025 Earnings Call, May 13, 2025
05-19	Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder	RE

Business description: Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Number of employees: 59

Sales by Activity: Altimmune, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Research and Development of Immunotherapies and Vaccines	8.19M	4.41M	-68K	426K	20K

See all business segments

Executive Committee: Altimmune, Inc.

Manager	Title	Age	Since
Vipin K. Garg CEO	Chief Executive Officer	68	2018-11-29
Gregory Weaver DFI	Director of Finance/CFO	69	2024-11-10
Randy Brown CTO	Chief Tech/Sci/R&D Officer	-	-
Anthony Blandin CMP	Compliance Officer	-	2022-01-31
M. Harris CTO	Chief Tech/Sci/R&D Officer	72	2019-09-08

See ALTIMMUNE, INC. governance

Composition of the Board of Directors: Altimmune, Inc.

Director	Title	Age	Since
Philip Hodges BRD	Director/Board Member	57	2003-08-31
Mitchel Sayare CHM	Chairman	77	2017-12-31
Klaus Schafer BRD	Director/Board Member	75	2012-06-30
Mack Gill BRD	Director/Board Member	73	2004-07-31
Wayne Pisano BRD	Director/Board Member	70	2018-08-29
Vipin K. Garg BRD	Director/Board Member	68	2018-11-29
Diane Jorkasky BRD	Director/Board Member	73	2020-05-10
Catherine Sohn BRD	Director/Board Member	71	2023-03-22
Teri Lawver BRD	Director/Board Member	58	2025-02-23
Jerome B. Durso BRD	Director/Board Member	57	2025-02-23

Composition of the Board of Directors

Shareholders: Altimmune, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 8.207 %	5,837,087	8.207 %	32 M $
Vanguard Fiduciary Trust Co. 6.197 %	4,407,462	6.197 %	24 M $
STATE STREET CORPORATION 4.768 %	3,391,571	4.768 %	18 M $
Tang Capital Management LLC 3.866 %	2,750,000	3.866 %	15 M $
Geode Capital Management LLC 2.398 %	1,705,885	2.398 %	9 M $

List of ALTIMMUNE, INC. shareholders

Company details: Altimmune, Inc.

Altimmune, Inc.

910 Clopper Road Suite 201S

20878, Gaithersburg

+240 654 1450

http://www.altimmune.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ALTIMMUNE, INC.	-3.22%	+23.13%	+13.26%	-24.12%	561M
REGENERON PHARMACEUTICALS, INC.	+1.42%	+7.30%	-48.94%	-3.49%	55.92B
ARGENX SE	-0.63%	-2.63%	+39.26%	+60.11%	35.47B
BEONE MEDICINES LTD.	-2.50%	+5.38%	+65.84%	+104.25%	34.36B
WUXI APPTEC CO., LTD.	+0.83%	+6.67%	+56.22%	-27.76%	27.41B
BIONTECH SE	+1.57%	-1.77%	+15.74%	-20.95%	25.62B
INSMED INCORPORATED	+1.91%	+34.11%	+54.46%	+467.74%	18.75B
SUMMIT THERAPEUTICS INC.	-1.88%	-3.93%	+135.76%	+1,999.34%	14.69B
WUXI BIOLOGICS (CAYMAN) INC.	+0.90%	+13.59%	+138.50%	-56.92%	14.51B
GENMAB A/S	-0.20%	+2.46%	-19.18%	-24.77%	14.14B
Average	-0.18%	+9.08%	+45.09%	+247.34%	24.14B
Weighted average by Cap.	+0.21%	+5.93%	+31.58%	+170.53%